Enyedy Mark J 4

What Happened Mark J. Enyedy, a director of BioMarin Pharmaceutical Inc. (BMRN), was granted 7,490 restricted stock units (RSUs) on June 2, 2026. The Form 4 reports the award as an acquisition (code A) with a reported price of $0.00; the filing footnote clarifies these are RSUs and price is not applicable. This is a compensation award rather than an open-market purchase.

Key Details

• Transaction date: 2026-06-02 (grant of 7,490 RSUs); filing date: 2026-06-04.
• Transaction code: A (award/grant); reported price: $0.00.
• Footnote: F1 — "Restricted stock units granted on June 2, 2026. Price not applicable."
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Filed within two days of the reported transaction date (appears timely).

Context Restricted stock units are a form of compensation subject to vesting and typically convert to shares in the future; they do not represent an immediate purchase or sale of stock. Such director RSU grants are common and are primarily compensation-related rather than a direct signal of insider buying or selling.